United Capital Financial Advisers, LLC Oncternal Therapeutics, Inc. Transaction History

United Capital Financial Advisers, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$2.27 - $4.39 $257,440 - $497,869	-113,410 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$3.37 - $4.76 $9,452 - $13,351	2,805 Added 2.54%	113,410 $473,000
Q1 2021 May 14, 2021	BUY	$4.59 - $9.04 $119,340 - $235,039	26,000 Added 30.73%	110,605 $920,000
Q1 2020 May 15, 2020	BUY	$2.49 - $4.39 $17,679 - $31,168	7,100 Added 9.16%	84,605 $248,000
Q4 2019 Feb 14, 2020	BUY	$3.75 - $6.11 $4,308 - $7,020	1,149 Added 1.5%	77,505 $306,000
Q3 2019 Nov 14, 2019	BUY	$3.87 - $6.13 $295,497 - $468,062	76,356 New	76,356 $382,000

362K

Ticker ONCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,517,200
Market Cap $29.4M
Description
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a smal...

Get notified when there are updates to the investment portfolio of United Capital Financial Advisers, LLC, based on Form 13F filings with the SEC.

Stay updated on United Capital Financial Advisers, LLC with notifications on news.